Voyager Therapeutics, Inc. 8-K

What Happened
Voyager Therapeutics (VYGR) announced GLP toxicology results for VY1706, its investigational tau‑silencing gene therapy for Alzheimer’s disease, presented July 13, 2026 at the Alzheimer’s Association International Conference. In non‑human primates (NHPs), a single intravenous dose produced broad, durable, dose‑dependent CNS delivery with up to 75% lowering of MAPT (tau) mRNA and tau protein in key AD‑relevant brain regions through six months. The company also disclosed FDA Investigational New Drug (IND) clearance for VY1706 in June 2026 and said it plans to begin dosing in a multi‑site, open‑label, dose‑escalation clinical trial in the second half of 2026.

Key Details

• Single IV dose in NHPs lowered MAPT mRNA and tau protein by up to 75% through six months.
• No adverse clinical pathology or histopathological findings in CNS, dorsal root ganglia, or peripheral organs (including liver) up to the highest tested dose of 5 x 10^13 vector genomes/kg (vg/kg).
• Data indicate ALPL (a conserved brain vasculature endothelial receptor) mediates VY1706 blood‑brain barrier transport, supporting potential cross‑species translatability.
• FDA granted IND clearance for VY1706 in June 2026; dosing in a multi‑site, open‑label, dose‑escalation trial is planned for H2 2026.

Why It Matters
These preclinical GLP results address two investor priorities: safety/tolerability and target engagement. The reported lack of adverse histopathology at doses up to 5 x 10^13 vg/kg and substantial, durable tau reduction in NHP brains support the program advancing to first‑in‑human testing. IND clearance and a planned H2 2026 start of clinical dosing move VY1706 from preclinical to clinical development — a key de‑risking step for the program. The filing also includes customary forward‑looking statements and risk disclosures noting outcomes, timelines, and translatability from animal studies to humans are subject to uncertainty.